19 October 2026 Trading and TGA Licensing Update – Q1 FY27 Dear Shareholders, Cryosite Limited (ASX: CTE) is pleased to provide the following update on its unaudited financial and operational performance for the quarter ended 30 September 2026 (Q1 FY27). The quarter delivered record trading...
Trading and TGA Licensing Update - Q1 FY27
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The company reported record trading results and a successful audit by the Therapeutic Goods Administration, which included both its South Granville headquarters and a new facility in Auburn. Additionally, Cryosite has completed an extension of its cool room capacity, which is expected to enhance its service offerings in response to increasing client demand. The outlook remains positive as the company anticipates continued momentum in the clinical trials market and is well-positioned for future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Cryosite
- 2026 AGM Notice of Meeting, Letter of Access and Proxy
- Notification of Date of 2026 AGM
- Appendix 4E and 2026 Annual Report
- Executive Director's Update FY26
- Appendix 4G and 2026 Corporate Governance Statement
Later from Cryosite
- Annual General Meeting Results
- Notification regarding unquoted securities - CTE
- Change of Director's Interest Notice - AK
- Change of Director's Interest Notice - ST
- Corporate Presentation - Bell Potter Healthcare Conference
Follow Cryosite into a list and get an email when it puts out news.
Follow Cryosite